Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

The average one-year price target for 10x Genomics (NasdaqGS:TXG) has been revised to $23.75 / share. This is an increase of 12.41% from the prior estimate of $21.13 dated April 12, 2026. The price ...

Enables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at Scale. Debuts at AACR Annual Meeting 2026 ...

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 5.4% in the afternoon session after a key industry peer, Thermo ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q1 CY2025 results , with sales up 9.8% year on year to $154.9 million. On the other hand, next quarter’s revenue guidance of $140 million was less ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

Collaboration enables researchers to begin exploring 10x single cell tools and datasets conversationally, with spatial applications to follow - making advanced analysis more accessible to the broader ...

PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to acquire ...

Investors usually find it discouraging when an analyst cuts the price target on one of their stocks. In this instance, the cut to this company's shares was rather deep. It wasn't immediately apparent ...

Collaboration with Dana-Farber Cancer Institute aims to identify biomarkers linked to treatment response for the next generation of cancer therapies and to define a clinical reporting framework to ...